Allogene Therapeutics, Inc. is a company in the U.S. stock market and it is a holding in 41 U.S.-traded ETFs. ALLO has around 3.3M shares in the U.S. ETF market. The largest ETF holder of ALLO is the iShares Russell 2000 ETF (IWM), with approximately 890.22K shares. Investors may also find of interest that the ETF with the largest allocation to ALLO stock is Loncar Cancer Immunotherapy ETF (CNCR), with a portfolio weight of 3.65%. On average, U.S. ETFs allocate 0.26% of ALLO to their portfolios.
Additionally, ALLO is a favorite stock for Vanilla and Equal ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with ALLO as a holding is the Virtus LifeSci Biotech Clinical Trials ETF (BBC), with a return of 34.78%.